Zwartkruis, Victor W. http://orcid.org/0000-0003-0115-1313
Suthahar, Navin
Idema, Demy L.
Mahmoud, Belend http://orcid.org/0000-0002-5703-248X
van Deutekom, Colinda http://orcid.org/0000-0001-5116-7378
Rutten, Frans H.
van der Schouw, Yvonne T. http://orcid.org/0000-0002-4605-435X
Rienstra, Michiel
de Boer, Rudolf A. http://orcid.org/0000-0002-4775-9140
Article History
Received: 10 March 2023
Revised: 24 August 2023
Accepted: 30 August 2023
First Online: 9 September 2023
Competing interests
: For the current manuscript, the authors declare no potential conflicts of interest. Outside of the submitted work, the authors disclosed the following financial support: RAdB reports grants from the Dutch Heart Foundation (CVON SHE-PREDICTS-HF, grant 2017-21; CVON RED-CVD, grant 2017-11; CVON PREDICT2, grant 2018-30; and CVON DOUBLE DOSE, grant 2020B005), leDucq Foundation (Cure PhosphoLambaN induced Cardiomyopathy) and the European Research Council (SECRETE-HF, ERC CoG 818715). RAdB has received research grants and/or fees from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals Gmbh, Ionis Pharmaceuticals, Inc., Novo Nordisk and Roche. RAdB has received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche. MR reports grants from the Dutch Heart Foundation (CVON RACE V, grant 2014-09; CVON RED-CVD, grant 2017-11; CVON-AI, grant 2018B017; DECISION, grant 2018B024). The UMCG, which employs MR, received grants from SJM/Abbott (VIP-HF study) and Medtronic (Cryoballoon AF registry/biobank study).